-
脑卒中是危害人类健康的主要疾病之一。根据国家卫健委最新颁布的《中国脑卒中防治指导规范(2021年版)》显示:脑卒中已成为我国居民第一大死因。缺血性脑卒中是最常见的脑卒中类型,占我国脑卒中的69.6%~70.8%。我国住院急性缺血性脑卒中患者发病后1个月内病死率为2.3%~3.2%,发病后1年内病死率为14.4%~15.4%,死亡/残疾率为33.4%~33.8%[1],缺血性脑卒中的致死率和致残率相当高。对于缺血性脑卒中的治疗,我们熟知的静脉溶栓、抗血小板、抗凝、降纤、扩容等方法,都是旨在改善脑血液循环,并非针对脑神经细胞的保护[2]。目前针对神经保护的药物较少,且疗效与安全性尚未被临床广泛接受。美国心脏病协会/美国卒中协会发布的《2019年急性缺血性卒中患者早期管理指南》中表示:目前没有任何假定具有神经保护作用的药物或非药物治疗能够证明改善缺血性脑卒中的预后[3]。国内最新脑卒中诊治指南也认为神经保护剂的疗效与安全性尚需要更多高质量临床试验来进一步证实[1]。目前的神经保护药物尚不能解决脑卒中患者遗留神经功能障碍的问题。
菸花苷是课题组从传统活血化瘀中药红花中研发的治疗急性脑缺血性脑卒中的中药1类新药,化学结构式如图1。课题组前期的研究表明,菸花苷对于动物缺血性脑卒中急性期具有预防和治疗作用[4],但是,菸花苷对脑缺血的长期治疗效果尚未见报道,其抗脑缺血作用机制的研究也有待进一步深入。本实验通过观察菸花苷对于大鼠长期生存率、神经系统功能、体重及脑神经元的影响,进一步探讨菸花苷对缺血性脑卒中的长期治疗效果及可能的作用机制。
Long-term protective effects of the nicotiflorin on ischemic stroke rats
-
摘要:
目的 探讨菸花苷对缺血性脑卒中大鼠的长期保护作用。 方法 建立大鼠脑缺血模型,观察菸花苷对于大鼠长期生存率、神经系统功能、体重及脑神经元的影响。 结果 菸花苷可以显著提高脑缺血大鼠的长期生存率,促进大鼠体重增加,减轻脑组织病理损伤,维持脑神经元形态及神经系统功能。 结论 菸花苷具有明显的对缺血性脑卒中大鼠的长期保护作用,其作用机制可能与保护脑神经元结构和功能有关。 Abstract:Objective To investigate the long-term protective effects of the nicotiflorin on ischemic stroke rats. Methods Ischemic stroke model in rats was established for this study. The effects of nicotiflorin on long-term survival rate, nervous system function, body weight and brain neurons in rats were observed. Results The nicotiflorin had significantly improved the long-term survival rate of cerebral ischemia rats, which also promoted weight gain, alleviated pathological damage of brain tissue, maintained morphology of brain neurons and function of nervous system. Conclusion The nicotiflorin has obvious long-term protective effect on ischemic stroke rats and the mechanism may be related to the protection of the structure and function of brain neurons. -
Key words:
- nicotiflorin /
- ischemic stroke /
- neuroprotection /
- pathology
-
-
[1] 国家卫生健康委脑卒中防治工程委员会, 中华医学会神经病学分会脑血管病学组. 中国脑卒中防治指导规范(2021年版) . (2021-08-27). http://www.nhc.gov.cn/wjw/index.shtml. [2] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9):666-682. doi: 10.3760/cma.j.issn.1006-7876.2018.09.004 [3] POWERS W J, RABINSTEIN A A, ACKERSON T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association[J]. Stroke,2019,50(12):e344-e418. [4] 王业晴, 夏玉叶, 唐颖, 等. 菸花苷对全脑缺血再灌注模型大鼠的脑保护作用[J]. 药学服务与研究, 2017, 17(2):109-113. [5] BELAYEV L, KHOUTOROVA L, ATKINS K D, et al. Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia[J]. Stroke,2009,40(9):3121-3126. doi: 10.1161/STROKEAHA.109.555979 [6] CHEN J L, YE X C, YAN T, et al. Adverse effects of bone marrow stromal cell treatment of stroke in diabetic rats[J]. Stroke,2011,42(12):3551-3558. doi: 10.1161/STROKEAHA.111.627174 [7] HASEGAWA Y, SUZUKI H, SOZEN T, et al. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats[J]. Stroke,2010,41(2):368-374. doi: 10.1161/STROKEAHA.109.568899 [8] SUZUKI Y, CHEN F, NI Y C, et al. Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI[J]. Stroke,2004,35(10):2402-2406. doi: 10.1161/01.STR.0000140628.00927.1a [9] DESLAND F A, AFZAL A, WARRAICH Z, et al. Manual versus automated rodent behavioral assessment: comparing efficacy and ease of bederson and garcia neurological deficit scores to an open field video-tracking system[J]. J Cent Nerv Syst Dis, 2014, 6: 7-14. DESLAND F A, AFZAL A, WARRAICH Z, et al. Manual versus automated rodent behavioral assessment: comparing efficacy and ease of bederson and garcia neurological deficit scores to an open field video-tracking system[J]. J Cent Nerv Syst Dis, 2014, 6:7-14. [10] PANG X M, LI T X, FENG L X, et al. Ellagic acid-induced thrombotic focal cerebral ischemic model in rats[J]. J Pharmacol Toxicol Methods,2014,69(3):217-222. doi: 10.1016/j.vascn.2014.01.001 [11] Stroke Therapy Academic Industry R. Recommendations for standards regarding preclinical neuroprotective and restorative drug development[J]. Stroke,1999,30:2752-2758. doi: 10.1161/01.STR.30.12.2752 [12] LI R P, GUO M L, ZHANG G, et al. Nicotiflorin reduces cerebral ischemic damage and upregulates endothelial nitric oxide synthase in primarily cultured rat cerebral blood vessel endothelial cells[J]. Journal of Ethnopharmacology,2006,107(1):143-150. doi: 10.1016/j.jep.2006.04.024 [13] LI R P, GUO M L, ZHANG G, et al. Neuroprotection of nicotiflorin in permanent focal cerebral ischemia and in neuronal cultures[J]. Biol Pharm Bull,2006,29(9):1868-1872. doi: 10.1248/bpb.29.1868 [14] SCHMIDT-KASTNER R, FREUND T F. Selective vulnerability of the Hippocampus in brain ischemia[J]. Neuroscience,1991,40(3):599-636. doi: 10.1016/0306-4522(91)90001-5 [15] HU H H, LI S J, WANG P, et al. An L-type calcium channel agonist, bay K8644, extends the window of intervention against ischemic neuronal injury[J]. Mol Neurobiol,2013,47(1):280-289. doi: 10.1007/s12035-012-8362-x